DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ARALEN
Clinical Trials for Aralen
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00224978 | Chloroquine for Treatment of Glioblastoma Multiforme | Completed | National Institute of Neurology and Neurosurgery, Mexico | Phase 3 | Chloroquine is a strong lysosomotropic and DNA-intercalating agent in experimental studies (Neurosurgical Focus 14(2): February, 2003) and an open-label clinical trial the investigators have demonstrated a strong adjuvant effect of chloroquine on the therapy of malignant gliomas. This study will assess in a randomized, placebo-controlled, double-blind study the effects of chloroquine as adjuvant to the conventional therapy of Glioblastoma Multiforme. |
| NCT00323375 | Phase 1 Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine | Completed | National Institutes of Health (NIH) | Phase 1 | The purpose of this protocol is to perform Phase 1 (safety/toxicity and pharmacokinetic) Studies of an investigational aminoquinoline antimalarial (AQ-13) in human subjects. The compound to be studied (AQ-13) is being examined because it is active in vitro against Plasmodium falciparum malaria parasites resistant to chloroquine (CQ) and other antimalarials (multi-resistant P. falciparum), and because its safety was similar to that of CQ in preclinical studies performed by SRI International (IND 55,670). AQ-13 was also selected for study because it is active in vivo in two monkey models of human malaria: 1] P. cynomolgi in the rhesus monkey (Macaca mulatta), a model of human infection with P. vivax, and 2] CQ-resistant P. falciparum in the squirrel monkey, a model of human infection with CQ-resistant P. falciparum. |
| NCT00323375 | Phase 1 Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine | Completed | Tulane University Health Sciences Center | Phase 1 | The purpose of this protocol is to perform Phase 1 (safety/toxicity and pharmacokinetic) Studies of an investigational aminoquinoline antimalarial (AQ-13) in human subjects. The compound to be studied (AQ-13) is being examined because it is active in vitro against Plasmodium falciparum malaria parasites resistant to chloroquine (CQ) and other antimalarials (multi-resistant P. falciparum), and because its safety was similar to that of CQ in preclinical studies performed by SRI International (IND 55,670). AQ-13 was also selected for study because it is active in vivo in two monkey models of human malaria: 1] P. cynomolgi in the rhesus monkey (Macaca mulatta), a model of human infection with P. vivax, and 2] CQ-resistant P. falciparum in the squirrel monkey, a model of human infection with CQ-resistant P. falciparum. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Aralen
Condition Name
Clinical Trial Locations for Aralen
Trials by Country
Clinical Trial Progress for Aralen
Clinical Trial Phase
Clinical Trial Sponsors for Aralen
Sponsor Name
| Sponsor Name for Aralen | |
| Sponsor | Trials |
| United States Department of Defense | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| National Institute of Neurology and Neurosurgery, Mexico | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
